Home

Resources and free materials for those living with low vision

View Resources

Live Your Best Life

This site offers up-to-date information and free materials for people living with low vision.

If you are also looking for personal support and contact with others who share your challenges and experiences, please visit our partners at Macular Degeneration Support.

Get Support

Popular Links

Reviews from the Community

  • “These are the most valuable publications a patient can have to navigate and transition into a successful low vision world.”

    • Liz Trauernicht, President, MD Foundation
  • “The booklets and CDs are WONDERFUL! They are going to tremendously help me help my patients.”

    • Karen Winegardner, COTA, LMT
  • “Thank you for providing such a wonderful and free service to assist those in need.”

    • Cornerstone Eye Care, High Point NC
  • "I wonder if you are aware of the great benefit you have provided others with vision problems. You have supplied information and hope in so many areas. Please keep it up."

    • Marie Miller, Patient
  • "A mass of well-organized information...fine resource for news, updates and answers to specific queries." (Jean)

    • Jean Lord, Patient

Need a Ride?

Our database includes more than 1500 paratransit services in cities across the country. You can search by location or business to find out exactly how to get around safely and comfortably in your area.

Search for Transportation

Latest News

  • February 22, 2020

    Anti-scarring angiogenic drug enters Phase 2

    RIBOMIC, Inc. has announced that the first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States. Currently approved therapies […]

  • February 22, 2020

    “How long will my anti-VEGF drug therapy be effective?”

    This is becoming a common question among people who have been treated for years with anti-VEGF drug therapy. These eye injections are the gold standard for treatment of wet age-related macular degeneration (wAMD), having been first used clinically in 2004. The news is good. A recent retrospective review in the U.K. has found that almost […]

  • February 17, 2020

    New discovery may lead to AMD treatment

    Researchers have discovered a protein that might be related to the cause of age-related macular degeneration (AMD) and thus provide insight into early diagnosis and treatment. The study, published in Nature Communications, was a collaboration of Queen Mary University of London, the University of Manchester, Cardiff University, and Radboud University Medical Center, Nijmegen. High levels […]

  • January 25, 2020

    Smoking Is At An All-Time Low

    For over two decades, eye health organizations have worked diligently to increase awareness of the high risks of macular degeneration from tobacco smoking. Now, the recently-released 2020 Surgeon General’s report has revealed that the work of those organizations is paying off. Americans are doing better at making good choices when it comes to smoking. According […]

  • January 9, 2020

    How Do They Come Up With Those Drug Names?

    Macugen. Lucentis. Avastin. Eylea. Beovu. All of those are anti-VEGF drugs prescribed for treatment of wet AMD and other conditions involving growth and leakage of new blood vessels in the retina. Those brand names appear in articles and ads, but rarely in eye specialists’ notes and prescription orders. Such names are designed mainly for public […]

  • December 17, 2019

    Trials to begin for stem cell-based therapy to treat geographic atrophy

    A National Eye Institute (NEI) study will test the safety of a stem cell treatment for the dry (atrophic) form of age-related macular degeneration (AMD). The researchers will take a patient’s own blood cells, and in a lab, convert them into induced pluripotent stem cells (iPSC) capable of becoming any type of cell in the […]

  • December 15, 2019

    Cognitive Decline Associated With AMD

    Investigators have found significant associations between lessened brain functions and age-related macular degeneration (AMD). 5604 people age 40+ who participated in the 2005-2008 National Health and Nutrition Examination Survey have been found to experience increased memory problems and confusion, seemingly as a result of their AMD. The report was published in the December 2019 issue […]

  • October 20, 2019

    Positive Results From RGX-314 Gene Therapy

    As reported here in 2017, a drug called RGX-314 is being tested as a one-time sub-retinal injection for wet age-related macular degeneration (wAMD). A preliminary study showed that patients with wAMD had long-term vision stabilization and anatomic improvement following a single treatment with the investigational gene therapy. Now, in a subgroup of patients with the […]

  • October 15, 2019

    Port Delivery System Shows Good Phase 2 Trial Results

    Genentech has reported end-of-trial results examining the use of their unique alternative to intravitreal injections, the Port Delivery System (PDS). As reported previously here, the PDS is a tiny refillable implant that provides patients affected by wet age-related macular degeneration (AMD) with continuous delivery of Lucentis (ranibizumab) as necessary. Presented by Carl Regillo, MD, at […]

  • October 14, 2019

    New Treatment Effective For Treatment of Dry AMD

    A Phase 2 study has found that a new drug could be a safe and effective treatment for improving vision in patients with dry age-related macular degeneration (AMD). On October 13, 2019, David Boyer, MD (Retina-Vitreous Associates Medical Group), presented results from a study of risuteganib intravitreal injection to members of the American Academy of […]

  • September 2, 2018

    Novel Gene Therapy In Trials for Wet AMD

    (Updated 10/12/19) Adverum Biotechnologies, Inc. has announced progress with yet another therapy designed to extend the time between anti-VEGF injections for treatment of wet age-related macular degeneration (wAMD). The company’s Investigational New Drug (IND) application has been approved for a multi-center study of ADVM-022, a novel gene therapy candidate for the treatment of wAMD. “We […]

  • Read All News